- Home
- BRY vs ATYR Comparison
BRY vs ATYR Comparison
Compare BRY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ATYR
- Stock Information
- Founded
- BRY 1909
- ATYR 2005
- Country
- BRY United States
- ATYR United States
- Employees
- BRY N/A
- ATYR N/A
- Industry
- BRY Oil & Gas Production
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRY Energy
- ATYR Health Care
- Exchange
- BRY Nasdaq
- ATYR Nasdaq
- Market Cap
- BRY 328.5M
- ATYR 330.7M
- IPO Year
- BRY N/A
- ATYR 2015
- Fundamental
- Price
- BRY $3.45
- ATYR $3.73
- Analyst Decision
- BRY Hold
- ATYR Strong Buy
- Analyst Count
- BRY 1
- ATYR 6
- Target Price
- BRY $5.00
- ATYR $18.60
- AVG Volume (30 Days)
- BRY 974.5K
- ATYR 1.9M
- Earning Date
- BRY 03-12-2025
- ATYR 03-13-2025
- Dividend Yield
- BRY 10.22%
- ATYR N/A
- EPS Growth
- BRY N/A
- ATYR N/A
- EPS
- BRY 0.25
- ATYR N/A
- Revenue
- BRY $783,841,000.00
- ATYR $235,000.00
- Revenue This Year
- BRY N/A
- ATYR $1,387.23
- Revenue Next Year
- BRY N/A
- ATYR $873.22
- P/E Ratio
- BRY $13.70
- ATYR N/A
- Revenue Growth
- BRY N/A
- ATYR N/A
- 52 Week Low
- BRY $3.06
- ATYR $1.42
- 52 Week High
- BRY $8.88
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- BRY 37.40
- ATYR 54.37
- Support Level
- BRY $3.06
- ATYR $2.98
- Resistance Level
- BRY $3.49
- ATYR $4.32
- Average True Range (ATR)
- BRY 0.24
- ATYR 0.39
- MACD
- BRY -0.01
- ATYR 0.06
- Stochastic Oscillator
- BRY 35.24
- ATYR 72.14
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.